Measuring plasma salicylate concentrations in all patients with drug overdose or altered consciousness: is it necessary?

D M Wood, P I Dargan, A L Jones

Background: Salicylate self-poisoning is potentially fatal. Plasma salicylate concentrations can be used to guide management when taken in the context of clinical features of toxicity and acid base status. Previous studies in the USA and Hong Kong have shown that routine measurement of plasma salicylate concentrations in all overdose patients is inappropriate, but there have been no previous studies in the UK.

Methods: A retrospective case note study from 1 February 2001 to 31 January 2002 was undertaken at the emergency department of St. Thomas’ Hospital, London. Records were reviewed and information on demographic data, history, details of salicylate overdose, and documentation of clinical features of salicylate toxicity recorded.

Results: In total, 722 patient episodes were identified, of which 596 case notes were available and appropriate for inclusion in this study. Plasma salicylate concentrations (range 15–428 mg/l) were detectable in 50 patients (three notes not available), of whom 38 had given a positive history. The history of salicylate poisoning had a sensitivity of 81% (95% confidence interval (CI) 67 to 91%) and the predictive value of a negative history of salicylate ingestion in not detecting salicylate concentrations was 98% (95% CI 97 to 99%). Insufficient information on clinical features of salicylate toxicity was recorded in 569 patients (including 35 patients who had a history of salicylate ingestion).

Conclusion: History of salicylate ingestion has a high sensitivity and negative predictive value with respect to the detection of plasma salicylate concentrations. However, current practice indicates that insufficient information is obtained from patients about the clinical features of toxicity. Routine measurement of plasma salicylate concentrations is not required unless there is (a) a positive history of ingestion of salicylates or (b) a reduced level of consciousness or other reason limiting the validity of the history obtained, together with clinical features consistent with salicylate poisoning.
specificity of 98% (95% CI 97 to 99%) for the detection of salicylate in patients plasma. The predictive value of a negative history of salicylate ingestion that salicylate would not be detected was 98% (95% CI 97 to 99%). This means that screening only those patients with a history of salicylate ingestion would miss only 2% of laboratory confirmed cases of salicylate ingestion.

**Clinical features of salicylate poisoning**

Only 27 (4.5%) patient episodes reviewed had sufficient information recorded in the admission cards concerning the presence or absence of symptoms and/or signs of salicylate poisoning. Of the 569 patients with insufficient information recorded on clinical features of salicylate poisoning, 35 had detectable salicylate concentrations, including the highest recorded concentration in this study of 428 mg/l.

**Salicylate concentrations**

Of the 50 patients with detectable plasma salicylate concentrations, three admission records were not available. The highest detectable plasma salicylate concentration was 428 mg/l, and no patient required intravenous sodium bicarbonate, urinary alkalinisation, or haemodialysis as part of the management of salicylate toxicity. Fig 1 shows the range of salicylate concentrations; in this study there was a greater frequency of positive history of salicylate ingestion in patients with higher plasma salicylate concentrations.

**DISCUSSION**

Incidences of salicylate poisoning have decreased in frequency in the UK, and consequently junior doctors in particular may not be as aware of the characteristic symptoms and signs. Initially, patients complain of sweating, nausea, and vomiting, and may have tinnitus, which tends to indicate a salicylate concentration >400–500 mg/l. Other signs of salicylate intoxication include sweating, flushing, bounding pulses secondary to peripheral vasodilatation, and initially a respiratory alkalosis. Signs of severe intoxication include a metabolic acidosis, renal failure, and central nervous system effects such as agitation, fitting, confusion, and coma. In all patients with suspected salicylate overdose, plasma salicylate concentrations should be measured at 2 hours in symptomatic patients or 4 hours in asymptomatic patients, but should be interpreted along with clinical state and any acid base disturbance. Salicylate forms concretions within the stomach, thereby delaying absorption, and plasma salicylate concentration measurements should be repeated until a peak has occurred.

Several studies in the 1970s and 1980s suggested that routine toxicological screening in all overdose patients frequently identifies unsuspected drugs. Based on these, some authors argue that routine toxicological screening of all suspected overdose patients should be undertaken. However, the fact that a toxicological screen may pick up a drug that was not suspected is rarely of clinical importance, and the results of toxicological screens rarely result in changes in the management of patients, thus they are therefore not used routinely in clinical toxicology practice. The list of drugs for which a drug concentration can be useful as an adjunct to clinical parameters is small (paracetamol, theophylline, lithium, iron, salicylates, and anticonvulsants).

Several studies that have addressed the question of the clinical value of screening for salicylates in patients presenting with self poisoning. These have studied different population groups and have identified patients either by salicylate concentrations measured or review of consecutive patients with a diagnosis of suspected drug overdose and are summarised in table 1. The sensitivity (range 28–93%) and negative predictive value (range 98–99%) of history or clinical suspicion of salicylate ingestion in these studies are similar to those identified in our study. Two studies reported treatment interventions required in patients who were identified by laboratory analysis alone. In both, maximum salicylate concentrations were below that requiring specific intervention for salicylate toxicity. Additionally, one was a follow up study at the same hospital following the group’s initial results that showed that routine measurement of salicylate concentrations was not appropriate. The follow up also showed similar results, suggesting that their initial findings had not altered clinical practice.

None of the above reported studies has commented on the physicians’ accuracy and degree of reporting of clinical features of salicylate toxicity. The recording of clinical features suggestive of a salicylate overdose was poor in our study. In a retrospective notes study, it is difficult to ascertain whether the documented findings truly represent the clinical features on admission to the ED. However, it should be noted that these features were also not recorded in the initial assessment of patients who had admitted to salicylate ingestion. Documentation of clinical features of salicylate toxicity is important, as their presence is one of the main factors determining management of these patients.

<table>
<thead>
<tr>
<th>Study</th>
<th>Country</th>
<th>Method of identification of patients</th>
<th>Sensitivity (%)</th>
<th>Negative predictive value (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>This study</td>
<td>UK</td>
<td>Positive salicylate concentrations</td>
<td>81</td>
<td>98</td>
</tr>
<tr>
<td>Sporer et al²</td>
<td>USA</td>
<td>Positive salicylate concentrations</td>
<td>28</td>
<td>N/A</td>
</tr>
<tr>
<td>Brett et al¹²</td>
<td>USA</td>
<td>Consecutive presenting overdose patients</td>
<td>93</td>
<td>98</td>
</tr>
<tr>
<td>Mahoney et al²</td>
<td>USA</td>
<td>Consecutive presenting overdose patients</td>
<td>88</td>
<td>99</td>
</tr>
<tr>
<td>Chan et al¹³</td>
<td>Hong Kong</td>
<td>Positive salicylate concentrations</td>
<td>93</td>
<td>99</td>
</tr>
<tr>
<td>Chan et al³⁴</td>
<td>Hong Kong</td>
<td>Positive salicylate concentrations</td>
<td>86</td>
<td>98</td>
</tr>
</tbody>
</table>

N/A, insufficient data available in paper for analysis to be calculated.
et al have shown that the use of a pre-formatted admission chart for patients presenting with self poisoning increases the recording of clinical symptoms and signs of poisoning. We now use a standardised pre-formatted toxicology admission sheet for all patients presenting to St Thomas' Hospital with self poisoning, to increase the validity of data collected on our patients.

One of the potential limitations of our study is that there were no patients with serious salicylate poisoning during the study period. However, it supports the findings of previous studies in Hong Kong and the USA that routine measurement of plasma salicylate concentrations in all patients presenting with self poisoning is not of clinical value, particularly as one of the main factors used to guide treatment of these patients is the presence of significant clinical features of toxicity. Thorough clinical assessment of the clinical features suggestive of salicylate intoxication (tinnitus, sweating, tachypnoea) would limit the number of salicylate concentrations measured in those patients who can give reliable histories. Patients with a reduced level of consciousness or significant intoxication with ethanol or other drugs, which could limit the validity of the history, or in whom the history is suspect should have salicylate concentrations measured.

Previous studies have shown that routine measurement of plasma salicylate concentrations following presentation with suspected self poisoning is inappropriate. This retrospective case note study shows that the patient’s history has a high sensitivity and specificity for the detection of plasma salicylate. Additionally, insufficient information is obtained and recorded on clinical features suggestive of salicylate toxicity, including those patients with a documented history of salicylate ingestion. Routine measurement of plasma salicylate concentrations is not required unless there is (a) a positive history of ingestion of salicylates or (b) a reduced level of consciousness or other reason limiting the validity of history obtained, together with the presence of clinical features consistent with salicylate poisoning (such as coma, metabolic acidosis, respiratory alkalosis, tinnitus). These recommendations are in line with a joint position paper by the National Poisons Information Service and the Association of Clinical Biochemists.

Authors’ affiliations
D M Wood, Pharmacology and Clinical Pharmacology, St George’s Hospital Medical School, London, UK
P I Dargan, A J Jones, National Poisons Information Service (London), Guy’s and St Thomas’ Hospital, London, UK

Competing interests: none declared

REFERENCES
Measuring plasma salicylate concentrations in all patients with drug overdose or altered consciousness: is it necessary?
D M Wood, P I Dargan and A L Jones

doi: 10.1136/emj.2003.010298

Updated information and services can be found at:
http://emj.bmj.com/content/22/6/401

These include:

**References**
This article cites 13 articles, 2 of which you can access for free at:
http://emj.bmj.com/content/22/6/401#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Poisoning (245)
- Poisoning/Ingestion (245)
- Drugs misuse (including addiction) (116)
- Unwanted effects / adverse reactions (31)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/